Literature DB >> 20414788

Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population.

Masakazu Nagahori1, Sea Bong Hyun, Teruji Totsuka, Ryuichi Okamoto, Erika Kuwahara, Toru Takebayashi, Makoto Naganuma, Mamoru Watanabe.   

Abstract

BACKGROUND: Metabolic syndrome (MS) is associated with an increased risk of cardiovascular disease. However, its prevalence in inflammatory bowel disease (IBD) patients remains largely unknown. This study was planned to determine the prevalence of MS in Japanese IBD patients.
METHODS: The prevalence of MS among outpatients with IBD aged 18 or older was studied using the modified National Cholesterol Education Program Adult Treatment Panel III definition.
RESULTS: A total of 107 quiescent IBD patients, including 76 ulcerative colitis (UC) patients and 31 Crohn's disease (CD) patients, were studied. Sufficient data were collected from a total of 102 patients. Prevalence of MS was significantly higher in UC (23.0%) patients compared to CD patients (7.1%). MS prevalence was substantially higher among male IBD patients (21.1%) compared to female IBD patients (12.9%), particularly in patients over 30 years of age. No difference was observed in the prevalence of MS between our IBD cohort and the general population in both males and females aged 40 years and older (P = 0.707 in males, P = 0.328 in females). IBD patients with MS were also older than those without (50.2 ± 15.0 vs. 38.0 ± 11.9 years, P = 0.013). In a logistic regression analysis, age was the statistically significant predictor of MS among IBD patients. The odds ratio (95% confidence interval) was 1.064 (1.017-1.114).
CONCLUSIONS: Prevalence of metabolic syndrome in our IBD patients was comparable to that of the general population. Because age was the independent risk factor for developing MS, evaluation for MS is needed for elderly IBD patients.

Entities:  

Mesh:

Year:  2010        PMID: 20414788     DOI: 10.1007/s00535-010-0247-z

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  33 in total

Review 1.  The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease.

Authors:  Konstantinos Karmiris; Ioannis E Koutroubakis; Elias A Kouroumalis
Journal:  Inflamm Bowel Dis       Date:  2005-09       Impact factor: 5.325

Review 2.  Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.

Authors:  Kwang Kon Koh; Seung Hwan Han; Michael J Quon
Journal:  J Am Coll Cardiol       Date:  2005-11-09       Impact factor: 24.094

3.  Coordinating preventive medicine in patients with inflammatory bowel disease: whose responsibility is it anyway?

Authors:  Alexandra Gutierrez
Journal:  Clin Gastroenterol Hepatol       Date:  2009-02-24       Impact factor: 11.382

Review 4.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

5.  Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group.

Authors:  M E Martínez; E Giovannucci; D Spiegelman; D J Hunter; W C Willett; G A Colditz
Journal:  J Natl Cancer Inst       Date:  1997-07-02       Impact factor: 13.506

6.  Inflammatory alterations in mesenteric adipose tissue in Crohn's disease.

Authors:  P Desreumaux; O Ernst; K Geboes; L Gambiez; D Berrebi; H Müller-Alouf; S Hafraoui; D Emilie; N Ectors; M Peuchmaur; A Cortot; M Capron; J Auwerx; J F Colombel
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

Review 7.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

8.  The impact of increased body mass index on the clinical course of Crohn's disease.

Authors:  David J Hass; Colleen M Brensinger; James D Lewis; Gary R Lichtenstein
Journal:  Clin Gastroenterol Hepatol       Date:  2006-04       Impact factor: 11.382

9.  Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County.

Authors:  Karen Vanessa Winther; Tine Jess; Ebbe Langholz; Pia Munkholm; Vibeke Binder
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

Review 10.  Metabolic syndrome and gastrointestinal diseases.

Authors:  Sumio Watanabe; Mariko Hojo; Akihito Nagahara
Journal:  J Gastroenterol       Date:  2007-04-26       Impact factor: 7.527

View more
  9 in total

1.  Glucose Metabolism Parameters and Post-Prandial GLP-1 and GLP-2 Release Largely Vary in Several Distinct Situations: a Controlled Comparison Among Individuals with Crohn's Disease and Individuals with Obesity Before and After Bariatric Surgery.

Authors:  Daniéla Oliveira Magro; Everton Cazzo; Paulo Gustavo Kotze; Ana Carolina Junqueira Vasques; Carlos Augusto Real Martinez; Elinton Adami Chaim; Bruno Geloneze; José Carlos Pareja; Cláudio Saddy Rodrigues Coy
Journal:  Obes Surg       Date:  2018-02       Impact factor: 4.129

Review 2.  Dietary management of IBD--insights and advice.

Authors:  Emma P Halmos; Peter R Gibson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

3.  Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy.

Authors:  José Miranda-Bautista; Celia de Gracia-Fernández; María López-Ibáñez; María Barrientos; Alejandra Gallo-Moltó; Marina González-Arias; Casilda González-Gil; Alicia Díaz-Redondo; Ignacio Marín-Jiménez; Luis Menchén
Journal:  Dig Dis Sci       Date:  2015-02-14       Impact factor: 3.199

4.  Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy.

Authors:  Linda A Feagins; Avegail Flores; Cristina Arriens; Christina Park; Terri Crook; Andreas Reimold; Geri Brown
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-10       Impact factor: 2.566

5.  Metabolic syndrome frequency in inflammatory bowel diseases.

Authors:  Elif Yorulmaz; Gupse Adali; Hatice Yorulmaz; Celal Ulasoglu; Guralp Tasan; Ilyas Tuncer
Journal:  Saudi J Gastroenterol       Date:  2011 Nov-Dec       Impact factor: 2.485

6.  Are adipocytokines inflammatory or metabolic mediators in patients with inflammatory bowel disease?

Authors:  Resul Kahraman; Turan Calhan; Abdurrahman Sahin; Kamil Ozdil; Zuhal Caliskan; Elif Sinem Bireller; Bedia Cakmakoglu
Journal:  Ther Clin Risk Manag       Date:  2017-09-30       Impact factor: 2.423

7.  Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.

Authors:  Salvatore Magrì; Danilo Paduano; Fabio Chicco; Arianna Cingolani; Cristiana Farris; Giovanna Delogu; Francesca Tumbarello; Mariantonia Lai; Alessandro Melis; Laura Casula; Massimo C Fantini; Paolo Usai
Journal:  World J Gastroenterol       Date:  2019-10-07       Impact factor: 5.742

Review 8.  Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.

Authors:  Che-Yung Chao; Robert Battat; Alex Al Khoury; Sophie Restellini; Giada Sebastiani; Talat Bessissow
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

9.  Metabolic syndrome in hypertensive women in the age of menopause: a case study on data from general practice electronic health records.

Authors:  Šefket Šabanović; Majnarić Trtica Ljiljana; František Babič; Michal Vadovský; Ján Paralič; Aleksandar Včev; Andreas Holzinger
Journal:  BMC Med Inform Decis Mak       Date:  2018-04-02       Impact factor: 2.796

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.